Search results for Lumretuzumab
Lumretuzumab Biosimilar – Anti-ERBB3 mAb – Research Grade, ProteoGenix, PX-TA1357
Description of Lumretuzumab Biosimilar - Anti-ERBB3 mAb - Research Grade General information on Anti-ERBB3[Homo sapiens] (Lumretuzumab) Monoclonal Antibody Lumretuzumab has been investigated for the treatment of Neoplasms, Breast Cancer, Non-Small Cell Lung Cancer.
Host
Reactivity
Applications
Conjugation
Lumretuzumab, Abbexa, abx831316
Lumretuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ERBB3, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Lumretuzumab Biosimilar - Research Grade, ichor.bio, ICH5660
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Research Grade Lumretuzumab (HB116026), abinScience, HB116026
Host
Humanized
Reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Conjugation
Please provide the required information below so that we can quickly source your products.